New hope for colorectal cancer in nigeria: immunotherapy trial launches
NCT ID NCT06529523
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study tests a drug called tislelizumab for people in Nigeria with a specific type of colorectal cancer (mismatch repair deficient). The drug helps the immune system attack cancer cells. The study will check if the drug shrinks tumors and is safe. It includes 40 adults who have not had cancer treatment before.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lagos University Teaching Hospital
NOT_YET_RECRUITINGIdi-Araba, Lagos, Nigeria
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
Obafemi Awolowo University Teaching Hospital
NOT_YET_RECRUITINGIle-Ife, Nigeria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?